Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWRX2003 + Remdesivir in Moderate-Severe COVID-19
NCT05226533Phase 2Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Proportion of subjects requiring mechanical ventilation and invasive mechanical ventilation or extra-corporeal membrane oxygenation (ECMO) at Day 14. Started Mar 2022; status: terminated.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05226533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226533.